# KLOW dosage & reconstitution (80 mg vial)

KLOW dosage: calculations for a 80 mg vial use the same amounts described in the literature. Adding 3 mL of bacteriostatic water produces 26.67 mg/mL, so each U-100 unit contains 267 mcg.

- **Vial contents:** 80 mg KLOW
- **Final volume:** 3 mL
- **Concentration:** 26.67 mg/mL
- **One U-100 unit:** 267 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (3 mL = ~26.67 mg/mL)

| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg | 0.9 units (0.01 mL) |
| Weeks 3–4 | 500 mcg | 1.9 units (0.02 mL) |
| Weeks 5–8 | 750 mcg | 2.8 units (0.03 mL) |
| Weeks 9–12 (Maintenance) | 500 mcg | 1.9 units (0.02 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 3 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 533.333 mcg | 150 injections |
| 5 | 0.05 mL | 1.33333 mg (1333 mcg) | 59 injections |
| 10 | 0.10 mL | 2.66667 mg (2667 mcg) | 29 injections |
| 20 | 0.20 mL | 5.33333 mg (5333 mcg) | 14 injections |
| 30 | 0.30 mL | 8 mg (8000 mcg) | 10 injections |
| 50 | 0.50 mL | 13.3333 mg (13333 mcg) | 5 injections |
| 100 | 1.00 mL | 26.6667 mg (26667 mcg) | 2 injections |

## Supplies Needed

**KLOW vials (80 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 1 vials (45.5 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 2 vials (87.5 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 3 mL total (3 mL per vial) → 1 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 6 mL total (3 mL per vial) → 2 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

KLOW is a research tetra-peptide blend in a single 80 mg lyophilized vial that combines two tissue-repair peptides (BPC-157 and TB-500), an α-MSH-derived anti-inflammatory tripeptide (KPV), and a copper tripeptide for dermal remodeling (GHK-Cu). The literature describes complementary pathways of angiogenesis, immune modulation, and extracellular matrix synthesis in experimental models. Blend composition (80 mg lyophilized per vial): BPC-157 (10 mg): pentadecapeptide derived from a gastric juice protective sequence. Preclinical literature documents upregulation of VEGFR2 (angiogenesis) and repair of tendon, ligament, and mucosa in murine models. Vasireddi N et al., Am J Sports Med 2025 (PMID 40756949) review 36 studies on the modulation of tissue repair pathways. TB-500 (10 mg): Synthetic fragment (LKKTETQ) of Thymosin Beta-4. Literature documents cell migration, angiogenesis via AC-SDKP, and cytokine modulation. Crockford D et al., Ann N Y Acad Sci 2010 (PMID 20955331) y Sosne G et al., Exp Eye Res 2002 (PMID 11819014) in healing models. KPV (10 mg): The Lys-Pro-Val tripeptide, derived from the C-terminal end of α-MSH. Literature documents an anti-inflammatory effect via PepT1…

---
Source: https://protocolopeptidos.com/en/compuestos/klow-80mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.